Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of E7389 in Patients With Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by:
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00069264
First received: September 19, 2003
Last updated: November 16, 2011
Last verified: November 2011

September 19, 2003
November 16, 2011
September 2003
March 2005   (final data collection date for primary outcome measure)
Determination of the Maximum Tolerated Dose [ Time Frame: 28 Days ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00069264 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of E7389 in Patients With Advanced Solid Tumors
A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) in Patients With Advanced Solid Tumors

To determine the maximum tolerated dose of E7389 in patients with advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Advanced Solid Tumors
Drug: E7389
E7389 Dose-escalation starting at 0.25 mg/m^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
Experimental: E7389
Intervention: Drug: E7389
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
July 2005
March 2005   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Patients must have a histologically or cytologically confirmed and measurable advanced solid tumor that has progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy)
  • Patients may have received prior chemotherapy
  • Patients must be aged > 18 years
  • Patients must have a Karnofsky Performance Status of > 70%
  • Patients must have a life expectancy of > 3 months
  • Patients must have adequate renal function as evidenced by serum creatinine <1.5mg/dL or creatinine clearance >= 45mL/minute
  • Patients must have adequate bone marrow function as evidenced by absolute neutrophil count > 1,500/µL and platelets > 100,000/µL
  • Patients must have adequate liver function as evidenced by bilirubin < 1.5mg/dL and alanine transaminase (ALAT) and aspartate transaminase (ASAT) <= 2 times the upper limits of normal (ULN)unless related to liver involvement by tumor, in which case <= 5.0 times ULN
  • Patients must be willing and able to comply with the study protocol for the duration of the study
  • Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice

Exclusion Criteria

  • Patients who have received chemotherapy within three weeks (six weeks if nitrosoureas were received) of E7389 treatment start
  • Patients who have not recovered from any chemotherapy related or other therapy related toxicity at study entry
  • Patients who require active anti-coagulant therapy
  • Women who are pregnant or breastfeeding. Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential)
  • Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception
  • Patients who have not successfully completed local therapy for previously treated central nervous system (CNS) metastases and who have not been discontinued from corticosteroids for at least four weeks before starting treatment with E7389. Patients with asymptomatic brain metastases who have no evidence of midline shift on CT scan or MRI may be enrolled without initiation of local therapy for the CNS metastases. In this case, a repeat scan must be performed within four weeks of the original scan to ensure that disease progression is not occurring.
  • Patients who have tested positive for HIV
  • Patients with severe uncontrolled intercurrent illness/infection (excluding malignancies)
  • Patients with uncontrolled cardiovascular illness defined as unstable angina, myocardial infarction within 6 months prior to study entry, symptomatic congestive heart failure (CHF) (NYHA II or higher) clinical evidence of CHF, or clinical evidence of serious cardiac arrhythmia
  • Patients with organ allografts
  • Patients who have received investigational drugs, including immunotherapy, gene therapy, hormone therapy, or other biologic therapy; anti-neoplastic therapy; or radiation therapy (other than required for palliation) within three weeks of E7389 treatment start
  • Patients who have had major surgery within four weeks of E7389 treatment start without a full recovery
  • Patients with a hypersensitivity to Halichondrin B and/or Halichondrin B-like compounds
  • Patients with other significant disease that, in the Investigator's opinion, would exclude the patient from the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00069264
E7389-A001-101, E7389, BOLD
Not Provided
Not Provided
Eisai Inc.
Not Provided
Study Director: Dale Shuster, Ph.D. Eisai Inc.
Eisai Inc.
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP